Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Nov 18, 2010

Premium

Title: Small Synthetic RNA, a Method of Preparing the Same, and Uses Thereof

Patent Number: 7,833,987

Filed: March 10, 2005 PCT Filed: March 10, 2005

Lead Inventor: Partho Sarothi Ray, Indian Institute of Science

"Translation of … hepatitis C virus RNA is mediated by the interaction of ribosomes and cellular proteins with an internal ribosome entry site located within the 5' untranslated region," the patent's abstract states. "We have investigated whether small RNA molecules corresponding to the different stem-loop domains of the HCV IRES, when introduced in trans, can bind to the cellular proteins and antagonize their binding to the viral IRES, thereby inhibiting HCV IRES-mediated translation. We have found that an RNA molecule corresponding to SL III of the HCV IRES could efficiently inhibit HCV IRES-mediated translation in a dose-dependent manner without affecting cap-dependent translation.

"The SL III RNA was also found to bind efficiently to most of the cellular proteins which interacted with the HCV 5' UTR," the abstract adds. "A smaller RNA corresponding to SL e+f of domain III also strongly and selectively inhibited HCV IRES-mediated translation. This RNA molecule showed strong interaction with the ribosomal S5 protein and prevented the recruitment of the 40S ribosomal subunit by the HCV IRES.

"In conclusion, our results demonstrate a novel approach to selectively block HCV RNA translation using a small RNA molecules mimicking the structure of the stem-loop IIIe+f subdomain of the HCV-IRES," it states. "The discovery provides a basis for developing a potent antiviral therapy targeting the interaction between the ribosome and the HCV-IRES RNA."


Title: siRNA Targeting Connective Tissue Growth Factor

Patent Number: 7,833,989

Filed: Dec. 23, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fischer Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CTGF."


Title: Conjugates and Compositions for Cellular Delivery

Patent Number: 7,833,992

Filed: April 30, 2003

Lead Inventor: Chandra Vargeese, Merck

"This invention features conjugates, degradable linkers, compositions, methods of synthesis, and applications thereof," the patent's abstract states. These include "cholesterol-derived conjugates of biologically active compounds including antibodies, antivirals, chemotherapeutics, peptides, proteins, hormones, nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids, DNAzymes, allozymes, antisense, dsRNA, siNA, siRNA, triplex oligonucleotides, 2,5-A chimeras, decoys, and aptamers."


Title: Functional and Hyperfunctional siRNA

Patent Number: 7,834,170

Filed: March 30, 2005

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fischer Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes."


Title: Short Nucleic Acid Molecule-Mediated Modulation of Aurora B Kinase Expression and Combinations for Use in Anti-Cancer Therapy

Application Number: 20100285107

Filed: Sept. 25, 2009

Lead Inventor: Murali Krishna Addepalli, Reliance Life Sciences

"This invention relates to the use of short nucleic acid molecules that modulate aurora-B kinase expression," the patent application's abstract states. "The invention includes compounds, compositions, and methods useful for the modulation of expression and activity of genes involved in the AurkB pathway. In one embodiment, the … invention provides short nucleic acid molecules, such as siRNA, which can be used in treating, preventing, or inhibiting cancer, and any other proliferative disease, trait, or condition, which respond to a reduction in AurkB expression in a cell or tissue. Such short nucleic acid molecules can be used alone or in combination with other treatments or therapies, including short nucleic acid molecules that modulate expression of EGFR."


Title: Self-Assembling Micelle-Like Nanoparticles for Systemic Gene Delivery

Application Number: 20100285111

Filed: Nov. 10, 2008 PCT Filed: Nov. 10, 2008

Lead Inventor: Young Tag Ko, Northeastern University

The invention, the patent application's abstract states, comprises "nanoparticles containing nucleic acid and suitable for use as in vivo delivery agents for nucleic acids. … The nanoparticles use a covalent conjugate of a polycation such as polyethylenimine and phospholipids. The final DNA-containing nanoparticle has a vesicular structure with a polyplex core surrounded by a mixed lipid/PEG-lipid monolayer envelope and offers simple preparation, high loading capacity, and in vivo stability. The nanoparticles have good in vivo stability and a prolonged blood circulation time and can effectively deliver a gene to a biological target such as a tumor."


Title: Methods of Delivering Oligonucleotides to Immune Cells

Application Number: 20100285112

Filed: May 5, 2010

Lead Inventor: Tatiana Novobrantseva, Alnylam Pharmaceuticals

"The invention relates to the field of delivery of nucleic acid-based agents to immune cells," the patent application's abstract states.


Title: Method of Inhibiting Intimal Hyperplasia

Application Number: 20100286228

Filed: June 1, 2006 PCT Filed: June 1, 2006

Inventor: Bruce Sullenger, Duke University

The invention relates to "intimal hyperplasia, and, in particular, to a method of inhibiting intimal hyperplasia using siRNA to E2F," according to the patent application's abstract. "The invention further relates to compounds and compositions suitable for use in such a method."


Title: Modulation of TRPV Expression Levels

Application Number: 20100286230

Filed: Oct. 20, 2006 PCT Filed: Oct. 20, 2006

Lead Inventor: Maria del Carmen Acosta Boj, Sylentis

The invention, the patent application's abstract states, "relates to methods and compositions for the treatment and/or the prevention of conditions related to high levels of expression and/or activity of the transient receptor potential vanilloid-1. Amongst others, the conditions to be treated are eye conditions such as discomfort and altered sensitivity of the cornea following refractive surgery, use of contact lenses, dry eyes, and diabetic retinopathy."


Title: microRNA Expression Level Associated with Pancreatic Cancer

Application Number: 20100286232

Filed: March 2, 2007 PCT Filed: March 2, 2007

Lead Inventor: Thomas Schmittgen, Ohio State University

The invention, the patent application's abstract states, comprises "methods … for diagnosing whether a subject has, or is at risk of developing, pancreatic cancer. The methods include measuring the level of at least one miR gene product in a biological sample derived from the subject's pancreas. An alteration in the level of the miR gene product in the biological sample as compared to the level of a corresponding miR gene product in a control sample, is indicative of the subject either having, or being at risk for developing, pancreatic cancer."


Title: microRNAs for Inhibiting Viral Replication

Application Number: 20100286240

Filed: Aug. 27, 2008 PCT Filed: Aug. 27, 2008

Inventor: Michael David, University of California, Oakland

The invention "relates to reducing accumulation of viral genomes in a target cell," the patent application's abstract states. "In particular, the … invention provides compositions and methods for combating viral infection through RNA interference. Specifically, the … invention provides cellular microRNA mimics for treating virus-infected subjects."


Title: siRNA-Mediated Gene Silencing of Synuclein

Application Number: 20100286242

Filed: Jan. 25, 2010

Lead Inventor: Martha Bohn, Children's Memorial Hospital

The invention comprises "small interfering RNAs that down regulate expression of a synuclein gene and methods of using the small interfering RNAs," the patent application's abstract states.


Title: Mig-7 as a Specific Anti-Cancer Target

Application Number: 20100286243

Filed: Oct. 22, 2008 PCT Filed: Oct. 22, 2008

Inventor: Suzanne Lindsey, Washington State University

"Aspects of the … invention provide novel Mig-7 encoding nucleic acids and Mig-7 polypeptides, RNAi, recombinant DNA-expression systems, and host cells containing same, as well as methods of inhibiting expression of the subject nucleic acid molecules, inhibiting production of the encoded proteins or polypeptides, inhibiting metastasis of a carcinoma cell in a subject, inhibiting migration/invasion of and mimicking of normal cells by carcinoma cells in a subject, detecting the presence of a cancer cell in a sample of a subject's tissue or body fluids, and inhibiting the migration/invasion of an endothelial cell mimicking by a placental cell into the blood stream or vessels of a female mammal," the patent application's abstract states. "Particular aspects relate to novel anti-Mig-7 antibodies, diagnostic and/or prognostic methods, and therapeutic methods comprising use of the inventive nucleic acids, polypeptides, and antibodies or derivatives thereof."


Title: RNAi-Mediated Knockdown of NuMA for Cancer Therapy

Application Number: 20100286244

Filed: April 30, 2010

Lead Inventor: Murali Addepalli, Reliance Life Sciences

"This invention relates to the use of short interfering nucleic acid molecules to inhibit nuclear mitotic apparatus protein gene expression and their use in treatment of disease including cancer," the patent application's abstract states.


Titles: Identification of Novel Genes Coding for Small Temporal RNAs

Application Numbers: 20100286245, 20100286246

Filed: May 7, 2010

Lead Inventor: Thomas Tuschl, Max Planck

"In Caenorhabditis elegans, lin-4 and let-7 encode 22- and 21 -nucleotide RNAs, respectively, that function as key regulators of developmental timing," the patent applications' abstracts state. "Because the appearance of these short RNAs is regulated during development, they are also referred to as small temporal RNAs. We show that many more 21- and 22-[nucleotide long] expressed RNAs, termed microRNAs, exist in invertebrates and vertebrates, and that some of these novel RNAs, similar to let-7 stRAN, are also highly conserved. This suggests that sequence-specific post-transcriptional regulatory mechanisms mediated by small RNAs are more general than previously appreciated."


Title: Composition of Asymmetric RNA Duplex as microRNA Mimetic or Inhibitor

Application Number: 20100286378

Filed: Aug. 27, 2008 PCT Filed: Aug. 27, 2008

Lead Inventor: Chiang Li, Boston Biomedical

The invention, the patent application's abstract states, comprises "double-stranded RNA molecules that are asymmetrical in strand length. The RNA molecule of the invention … has one or two overhangs at the end. In one aspect, these novel RNA duplex molecules serve as effective mimetics of miRNA. In another aspect, they are designed to function as effective inhibitors of miRNA. Accordingly, the RNA molecules of the … invention can be used to modulate miRNA pathway activities."

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.